Agios Pharmaceuticals Q4 2022 Earnings Report $32.42 +0.60 (+1.89%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Agios Pharmaceuticals EPS ResultsActual EPS$0.67Consensus EPS -$1.59Beat/MissBeat by +$2.26One Year Ago EPSN/AAgios Pharmaceuticals Revenue ResultsActual Revenue$4.31 millionExpected Revenue$4.42 millionBeat/MissMissed by -$110.00 thousandYoY Revenue GrowthN/AAgios Pharmaceuticals Announcement DetailsQuarterQ4 2022Date2/23/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseAGIO Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Agios Pharmaceuticals Earnings HeadlinesAgios Pharma (AGIO) Gets a Buy from Bank of America SecuritiesJanuary 16 at 8:13 PM | markets.businessinsider.comY-Mabs Therapeutics (YMAB) Gets a Hold from Bank of America SecuritiesJanuary 16 at 3:11 PM | markets.businessinsider.comMore AI patents than Nvidia, OpenAI and Tesla combinedIf you own a smartphone, there’s a good chance you’re already benefiting from its technology—because it’s on hundreds of millions of devices worldwide. But you don’t see it’s logo on the outside of the tech gadgets you buy… That’s because it’s on the inside, making up the app’s and components that run your smartphone, your computer, and everything else… January 18, 2025 | The Oxford Club (Ad)Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America SecuritiesJanuary 15 at 2:32 PM | markets.businessinsider.comAgios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA DecisionJanuary 14, 2025 | seekingalpha.comAgios Pharmaceuticals announces key 2025 milestones, catalysts through 2026January 13, 2025 | msn.comSee More Agios Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Agios Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agios Pharmaceuticals and other key companies, straight to your email. Email Address About Agios PharmaceuticalsAgios Pharmaceuticals (NASDAQ:AGIO), a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.View Agios Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
